TytoCare
Total Raised
$150.5MInvestors Count
19Deal Terms
2TytoCare Funding, TytoCare Valuation & TytoCare Revenue
8 Fundings
TytoCare's latest funding round was a Series D - II for $50M on March 4, 2021.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
---|---|---|---|---|---|---|
3/4/2021 | Series D - II | $50M | 23 | |||
7/20/2020 | Biz Plan Competition | |||||
4/7/2020 | Series D | |||||
1/16/2019 | Series C - II | |||||
1/29/2018 | Series C |
Date | 3/4/2021 | 7/20/2020 | 4/7/2020 | 1/16/2019 | 1/29/2018 |
---|---|---|---|---|---|
Round | Series D - II | Biz Plan Competition | Series D | Series C - II | Series C |
Amount | $50M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 23 |
TytoCare Deal Terms
2 Deal Terms
TytoCare's deal structure is available for 2 funding rounds, including their Series B from July 15, 2015.
Round | Series B | Series A |
---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
TytoCare Investors
19 Investors
TytoCare has 19 investors. Shenzhen Capital Group invested in TytoCare's Series D - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
---|---|---|---|---|---|---|
1/16/2019 | 3/4/2021 | 2 Series C - II, Series D - II (2021) | Venture Capital | China | ||
4/7/2020 | 3/4/2021 | 2 Series D, Series D - II (2021) | Corporate Venture | California | ||
4/7/2020 | 3/4/2021 | 2 Series D, Series D - II (2021) | Venture Capital | Israel | ||
Venture Capital | New York | |||||
Venture Capital | Israel |
First funding | 1/16/2019 | 4/7/2020 | 4/7/2020 | ||
---|---|---|---|---|---|
Last Funding | 3/4/2021 | 3/4/2021 | 3/4/2021 | ||
Investor | |||||
Rounds | 2 Series C - II, Series D - II (2021) | 2 Series D, Series D - II (2021) | 2 Series D, Series D - II (2021) | ||
Board Seats | |||||
Type | Venture Capital | Corporate Venture | Venture Capital | Venture Capital | Venture Capital |
Location | China | California | Israel | New York | Israel |
You May Also Like

Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology for pharmaceutical companies to demonstrate value, and cost-effective solutions for payers. Biofourmis has built Biovitals, a personalized, AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain. The company was founded in 2015 and is based in Boston, Massachusetts.

Eko creates digital health solutions including AI-enabled stethoscopes, patient and provider software, and AI-powered analytics that enable doctors, nurses, researchers, and entire health systems to change care for the heart.

AliveCor focuses on the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is a clinically validated mobile EKG solution on the market. It is recommended by cardiologists and used by people worldwide for accurate EKG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an EKG.

Glooko's universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. Glooko's systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake.

MC10 is developing electronic systems through its Conformal Electronics Platform. The platform enhances and enables applications by allowing electronics to occupy spaces and geometries not possible in traditional, rigid form. Backed by a patent portfolio secured both through in-licensing and continued developments at MC10, the company is targeting applications in consumer electronics, medical devices, industrial products, and defense systems.

VitalConnect currently markets the VitalConnect Platform that includes two wearable biosensors combined with mobile and cloud-based software and analytics. HealthPatch MD and VitalPatch biosensors are wireless, adhesive patches that continuously monitor and record single-lead ECG, heart rate, heart rate variability, respiratory rate, skin temperature, posture, step count, and fall detection with clinical accuracy. Through the VitalConnect Platform, care teams receive accurate data and notifications to make health decisions and enable timely interventions.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.